Skip to main content
. Author manuscript; available in PMC: 2020 Oct 11.
Published in final edited form as: ACS Infect Dis. 2019 Aug 12;5(10):1802–1812. doi: 10.1021/acsinfecdis.9b00237

Fig 1. Proteasome inhibitors decrease worm motility and induce caspase activity.

Fig 1.

Experiments employed 24 well plates with 5–6 adult S. mansoni pairs per well. A. At each time point, WormAssay recordings were taken over 45 – 60 sec and the mean motility value per well noted. For bortezomib (BTZ) and carfilzomib (CFZ), the decrease in motility at 6 and 24 h relative to the 1 h time point is significant (*p < 0.05; ** p < 0.005) by the Student’s t-test. B. Protein lysates were generated from S. mansoni worms following 24 h treatment with vehicle (Veh; 0.0001% DMSO) or 1 μM proteasome inhibitors. Caspase activity was quantified using the fluorogenic peptide substrate, Ac-DEVD-AFC. Caspase activity (relative fluorescent units/min/μg) was significantly (*p < 0.05) increased in lysates from worms treated with bortezomib and carfilzomib, but not MG132, compared to vehicle control. Data shown are from experiments performed in triplicate: in one experiment, duplicate wells were used per treatment, whereas in the second and third experiments, quadruplicate wells were used, thus yielding a total of 10 wells per treatment.